Company intelligence / Profile preview

Lofarma S.p.A.

Ownership: Private
Employees: ~92
Development stage: Commercial

Overview

Lofarma S.p.A. develops and markets specific immunotherapies and diagnostic tools for allergic respiratory diseases. Several products are approved and commercialized in Europe for the treatment of allergic rhinitis, conjunctivitis, and hypersensitivity to various allergens. The company continues to invest in R&D with ongoing clinical programs.

Therapeutic areas: Immunology
Modalities: Allergen extractsTherapeutic vaccinesImmunotherapies
Industry: Biotech

Drug pipeline

21 assets

sublingual monomeric allergoid

Unknown

20 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Lofarma S.p.A..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lofarma S.p.A..

Explore the full profile